DPP4 and Hypoglycemia: Importantly,DPP4 inhibitors do not reduce blood glucose under normoglycemic conditions,thereby minimising the risk of hypoglycemia and supporting their potential as a safe therapeutic strategy for CD-associated fibrosis.35